BioChem Pharma Inc. announced Tuesday that it will soonbegin several Phase II/III clinical trials of its drug 3TC in HIV-infected patients. The trials will compare 3TC, which is an anti-viral nucleoside, alone and in combination with AZT, to AZT orto AZT plus ddC, in early and advanced HIV infection.
London-based Glaxo, the Laval, Quebec, company's collaboratoron 3TC, will conduct trials in the U.S. under an investigationalnew drug (IND) application and has filed similar applications inother countries.
BioChem Pharma's stock (NASDAQ:BCHXF) closed at $12.75 pershare on Tuesday, up 25 cents.
(c) 1997 American Health Consultants. All rights reserved.